Attovia Therapeutics, Inc. share price logo

Attovia Therapeutics, Inc.

NASDAQ: ATTO

$24.52

+1.73

(+7.59%)

as on

Attovia Therapeutics, Inc. Stock Performance

as on September 15, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $22.28
    $25.30
    downward going graph

    9.14%

    Downside

    3.18%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Attovia Therapeutics, Inc. share price movements today

Previous Close
$22.79
Open
$22.28
Volume
337.2K
Market Cap
$1.0B
Day's Low - High
$22.28 - $25.30

Attovia Therapeutics, Inc. Historical Returns

1 Month Return
+ 23.46 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
-10.25 %

Attovia Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Attovia Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.0B

EPS (TTM)

-0.93

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-24.51

Industry PE ratio

-6.76

PEG Ratio

0.2959724778238842

EBITDA

-41.3M

Revenue (TTM)

450.0K

Profit Margin

-8.44%

Return On Equity TTM

-32.05%

Attovia Therapeutics, Inc. Stock Valuation

Track how Attovia Therapeutics, Inc. P/E has moved over time to understand its valuation trends.

Attovia Therapeutics, Inc. in the last 2 years

  • Overview

  • Trends

Lowest (-20.86x)

December 31, 2024

Today (-15.42x)

December 31, 2025

Industry (-6.76x)

December 31, 2025

Highest (-15.42x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -15.42x

Attovia Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Attovia Therapeutics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Attovia Therapeutics, Inc. image
Attovia Therapeutics, Inc.
BUY$1.0B-10.25%-24.51-8.44%NA
Revolution Medicines image
Revolution Medicines
BUY$44.6B614.61%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$130.6B175.08%29.7686.04%NA
Moderna image
Moderna
BUY$57.5B-66.24%-18.04-12.57%NA
Regeneron image
Regeneron
BUY$80.5B21.74%18.9584.86%47.339999999999996%

Stock Returns calculator for Attovia Therapeutics, Inc. Stock including INR - Dollar returns

The Attovia Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 5Y

  • 7Y

  • 10Y

Attovia Therapeutics, Inc. investment value today

Current value as on today

₹1,16,432

Returns

₹16,432

(+16.43%)

Returns from Attovia Therapeutics, Inc. Stock

-₹10,249 (-10.25%)

Dollar Impact

₹26,681 (+26.68%)

Analyst Recommendation on Attovia Therapeutics, Inc. Stock

Based on 4 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 4 analysts, 100% of analysts recommend a 'BUY' rating for Attovia Therapeutics, Inc.. Average target price of $42.2

Attovia Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Attovia Therapeutics, Inc..

What analysts predicted

41.9%UPSIDE

Target Price

$42.2

Current Price

$24.52

Analyzed by

4 Analysts

Target

$42.20

Attovia Therapeutics, Inc. target price $42.2, a slight upside of 41.9% compared to current price of $24.52. According to 4 analysts rating.

Indian Investors' Interest in Attovia Therapeutics, Inc. Stock

Search interest for Attovia Therapeutics, Inc. Stock has decreased by -31% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-31% versus previous 30 day period

Attovia Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Mar 2026
Jun 2026
Total Revenue
369
370
382
368
327
356
363
346
-
0
Gross Profit
348
349
353
346
305
329
333
311
0
0
Operating Income
22
8
22
20
-365
4
0
13
-19
-21
EBITDA
62
56
60
60
-290
-24
31
58
-19
-21
Interest Expense
18
24
22
18
27
18
20
13
-
-
Depreciation
30
30
28
30
43
31
31
30
0
0
Income Before Tax
-2
-19
-5
-4
-54
-74
-15
14
-18
-20
Income Tax Expense
5
0
9
6
-10
-4
-3
13
-
-
Net Income
-7
-20
-14
-11
-43
-70
-12
1
-18
-20
Net Profit Margin
94.29%
94.35%
92.49%
94.01%
93.28%
92.31%
91.73%
89.82%
0.00%
45.33%

Attovia Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2024
Dec 2025
Total Revenue
1,921
1,818
1,707
1,412
1,449
-
1
Gross Profit
1,846
1,747
1,640
1,340
1,355
0
0
Operating Income
92
89
63
56
72
-41
-67
EBITDA
204
203
204
176
232
-41
-66
Interest Expense
78
45
68
69
91
-
-
Depreciation
104
95
140
120
133
0
0
Income Before Tax
-1
33
-44
-41
-84
-39
-60
Income Tax Expense
12
13
36
5
5
-
-
Net Income
-16
18
-80
-46
-90
-39
-60
Net Profit Margin
96.10%
96.11%
96.11%
94.88%
93.53%
0.00%
40.44%

Attovia Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Mar 2026
Jun 2026
Net Income
-2
-19
-5
-4
-54
-74
-15
14
-18
-20
Operating Cash Flow
60
0
14
26
1
-30
27
-1
-18
-16
Investing Cash Flow
-10
-7
-16
-10
-14
-13
-8
-11
22
6
Financing Cash Flow
-36
-14
-30
-14
0
4
-10
-18
-1
0
Change in Cash
12
-32
-22
-8
-16
-31
5
-36
43
-10

Attovia Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2024
Dec 2025
Net Income
-1
33
-44
-41
-84
-45
-60
Operating Cash Flow
114
81
46
128
42
-35
-59
Investing Cash Flow
-90
-41
-56
-38
-50
-39
-73
Financing Cash Flow
-84
-33
5
0
-58
82
142
Change in Cash
-52
-8
-8
84
-80
30
9

Global Institutional Holdings in Attovia Therapeutics, Inc.

Funds
Holdings
HPS Investment Partners, LLC
0%
Farallon Capital Management, L.L.C.
0%
Morgan Stanley - Brokerage Accounts
0.57%
TWO SIGMA SECURITIES, LLC
0.2%
Goldman Sachs Group Inc
0.13%
See all

Insights on Attovia Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, ATTO stock has moved up by 5100.4%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ATTO has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ATTO has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -14.43M → -20.68M (in $), with an average decrease of 20.1% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 363.83M → 450.0K (in $), with an average decrease of 52.3% per quarter

About Attovia Therapeutics, Inc.

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
OrganisationAttovia Therapeutics, Inc.
Headquarters1091 Industrial Road, San Carlos, CA, United States, 94070
IndustryBiotechnology
CEOMr. Tao Fu M.B.A., M.S.
E-voting on sharesClick here to vote

Key Management of Attovia Therapeutics, Inc.

Name

Title

Dr. Hubert C. Chen M.D., M.P.H.

Chief Medical Officer

Mr. Steven Chan CPA

Chief Financial Officer

Dr. Hangjun Zhan Ph.D.

Chief Technology Officer

Dr. Bora Han Ph.D.

VP & Head of Preclinical Development

Dr. Zaneta Odrowaz Ph.D.

Chief Business Officer, Treasurer & Secretary

Mr. Tao Fu M.B.A., M.S.

CEO, President & Director

Dr. Petter Veiby Ph.D.

Chief Scientific Officer

FAQs

What is Attovia Therapeutics, Inc. share price today?

Attovia Therapeutics, Inc. share price today is $24.52 as on at the close of the market. Attovia Therapeutics, Inc. share today touched a day high of $25.30 and a low of $22.28.

What is the 52 week high and 52 week low for Attovia Therapeutics, Inc. share?

Attovia Therapeutics, Inc. share touched a 52 week high of $0.00 on and a 52 week low of $0.00 on . Attovia Therapeutics, Inc. stock price today i.e. is closed at $24.52,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Attovia Therapeutics, Inc.'s market capitalisation today?

Attovia Therapeutics, Inc. market capitalisation is $0.00T as on .

How to invest in Attovia Therapeutics, Inc. Stock (ATTO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Attovia Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Attovia Therapeutics, Inc. Shares that will get you 0.0612 shares as per Attovia Therapeutics, Inc. share price of $24.52 per share as on September 15, 2026 at 8:45 am IST.

What is the minimum amount required to buy Attovia Therapeutics, Inc. Stock (ATTO) from India?

Indian investors can start investing in Attovia Therapeutics, Inc. (ATTO) shares with as little as ₹95.54 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.40 in Attovia Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Attovia Therapeutics, Inc. share’s latest price of $24.52 as on September 15, 2026 at 8:45 am IST, you will get 0.4078 shares of Attovia Therapeutics, Inc.. Learn more about fractional shares .

What are the returns that Attovia Therapeutics, Inc. has given to Indian investors in the last 5 years?

Attovia Therapeutics, Inc. stock has given -10.25% share price returns and 29.75% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?